Modes of toxic action

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

Retrieved on: 
Thursday, February 16, 2023
Trial of the century, Lead, HPV, Cue, Cell signaling, Head, Selective, Nature, Patient, Signal transduction, University, Research, Modes of toxic action, Concept, Poster, Kennedy Institute, Kennedy Institute of Ethics Journal, Vaccine

The research is part of a strategic research collaboration that Cue Biopharma initiated with Dr. Michael Dustin’s laboratory at the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of the company’s interleukin 2 (IL-2) based CUE-100 series of biologics.

Key Points: 
  • The research is part of a strategic research collaboration that Cue Biopharma initiated with Dr. Michael Dustin’s laboratory at the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of the company’s interleukin 2 (IL-2) based CUE-100 series of biologics.
  • “The data continue to support the differentiated mechanism of action of Cue Biopharma’s Immuno-STAT CUE-100 series of biologics, by uniquely mimicking the natural process of immune synapse formation,” said Jesusa Capera-Aragones, Ph.D., post-doctoral researcher, Dustin laboratory of the Kennedy Institute at the University of Oxford.
  • “By simultaneously presenting a targeted antigen and the immunostimulatory molecule IL-2, Cue Biopharma’s biologics enable the specific and simultaneous engagement of IL-2 and T cell receptors, as it would occur in nature.
  • Dr. Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, added “We are very pleased with the research and collaboration with Dr. Dustin’s laboratory of the Kennedy Institute at the University of Oxford.

Kenjockety Biotechnology Reports Preclinical Results for Tumor-Focused, Bispecific Antibody (BsAb) Targeting P-Glycoprotein (Pgp) and CD47 at SITC 2021 (Abstract 282)

Retrieved on: 
Friday, November 12, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, PGP, Family, SITC, Combat, Cancer, Neoplasm, Modes of toxic action, Drug resistance, TAA, Engineering, Biotechnology, CEO, Doctor of Philosophy, Extended play, Society, CD47, Bispecific monoclonal antibody, DC, Annual general meeting, Therapy, Immunotherapy, Paclitaxel, Patient, TAAS, IND, Vaccine

These data will be shared in a poster presentation at the Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting in Washington, DC.

Key Points: 
  • These data will be shared in a poster presentation at the Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting in Washington, DC.
  • These results demonstrate proof-of-concept for our lead bispecific antibody which is now ready for IND enabling studies, said Robert Arathoon, PhD , Founder and CEO of Kenjockety Biotechnology.
  • The presentation includes preclinical results demonstrating in vivo efficacy for a Pgp X CD47 BsAb, both as monotherapy and in combination with paclitaxel in multiple tumor models.
  • Additionally, Kenjocketys results illustrate tumor-specific targeting by engineering BsAbs to have strong binding only in the presence of both targets.